Home › Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
 

Keywords :   


Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

2016-06-20 18:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orRobert Consalvo, (908) 295-0928orInvestor:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results study presented combination

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.05Asahi Photoproducts wins FTA Sustainability Excellence Award
06.05Bertz selected as new Executive Director
06.05Sun Bum Teams with Skin Cancer Foundation to Provide Free Skin Exams for Skin Cancer Awareness Month
06.05Miraclon\'s Shine LED Lamp Kit recognized twice by FTA
06.05Murad Unveils Stress Less Supplement Skin Health Booster
06.05Alo Yoga Adds New Supplements for Wellness & Longevity
06.05Mel Weiss, Founder of Consumer Product Testing Company, Dies
06.05Seek Labs reports breakthrough in treatments for ASF utilizing CRISPR
More »